CO2017005240A2 - Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción - Google Patents

Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción

Info

Publication number
CO2017005240A2
CO2017005240A2 CONC2017/0005240A CO2017005240A CO2017005240A2 CO 2017005240 A2 CO2017005240 A2 CO 2017005240A2 CO 2017005240 A CO2017005240 A CO 2017005240A CO 2017005240 A2 CO2017005240 A2 CO 2017005240A2
Authority
CO
Colombia
Prior art keywords
hetero
immunoglobulins
dimer
production methods
cell redirection
Prior art date
Application number
CONC2017/0005240A
Other languages
English (en)
Inventor
Romain Ollier
Samuel Hou
Darko Skegro
Rami Lissilaa
Jonathan Back
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of CO2017005240A2 publication Critical patent/CO2017005240A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a inmunoglobulinas hetero-diméricas que dirigen un componente del antígeno CD3 humano y un componente del antígeno CD38 humano y a métodos para fabricar el mismo; la presente invención también se refiere a anticuerpos que se unen al antígeno CD38 humano y sus derivados para usarse como reactivos terapéuticos o de diagnóstico y métodos para fabricarlos.
CONC2017/0005240A 2015-05-08 2017-05-26 Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción CO2017005240A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15167034 2015-05-08
PCT/EP2015/075628 WO2016071355A1 (en) 2014-11-04 2015-11-03 Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Publications (1)

Publication Number Publication Date
CO2017005240A2 true CO2017005240A2 (es) 2017-10-31

Family

ID=53059011

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005240A CO2017005240A2 (es) 2015-05-08 2017-05-26 Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción

Country Status (20)

Country Link
EP (1) EP3215541A1 (es)
JP (3) JP2018501297A (es)
KR (1) KR20170078831A (es)
CN (1) CN107207596A (es)
AU (1) AU2015341884B2 (es)
BR (1) BR112017009263A2 (es)
CA (1) CA2965745C (es)
CL (1) CL2017001090A1 (es)
CO (1) CO2017005240A2 (es)
EA (1) EA039658B1 (es)
HK (1) HK1244014A1 (es)
IL (1) IL251848A0 (es)
MA (1) MA40894A (es)
MX (1) MX2017005814A (es)
MY (1) MY186929A (es)
NZ (1) NZ732019A (es)
PE (1) PE20171041A1 (es)
PH (1) PH12017500819A1 (es)
SG (1) SG11201703313SA (es)
WO (1) WO2016071355A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
HRP20220553T1 (hr) 2013-07-25 2022-06-10 Cytomx Therapeutics Inc. Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
PE20160724A1 (es) 2013-11-04 2016-08-04 Glenmark Pharmaceuticals Sa Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t
EP3954713A3 (en) 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
CA2967426A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
MX2018015592A (es) 2016-06-14 2019-04-24 Xencor Inc Anticuerpos inhibidores de puntos de control biespecificos.
MX2019012606A (es) * 2017-04-24 2019-12-02 Ichnos Sciences SA Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.
JP7247110B2 (ja) 2017-06-05 2023-03-28 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｃｄ３抗体
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
JP7237950B2 (ja) * 2017-06-08 2023-03-13 ブラック ベルト セラピューティクス リミテッド Ｃｄ３８調節抗体
US11780930B2 (en) 2017-06-08 2023-10-10 Black Belt Therapeutics Limited CD38 modulating antibody
CN117820498A (zh) * 2017-08-10 2024-04-05 盖立复诊断解决方案公司 包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
EP3668543A1 (en) 2017-08-16 2020-06-24 Black Belt Therapeutics Limited Cd38 antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
JP7438106B2 (ja) 2017-10-14 2024-02-26 シートムエックス セラピューティクス，インコーポレイテッド 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法
KR20210075101A (ko) * 2018-09-25 2021-06-22 아이크노스 사이언스 에스. 아. 생물학적 샘플에서의 항체 정량법
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
AU2020211728A1 (en) * 2019-01-23 2021-08-12 Encefa CD31 competitors and uses thereof
EP3938398A2 (en) * 2019-03-13 2022-01-19 Ichnos Sciences S.A. Non-consensus glycosylation of bispecific antibodies
AU2020277489A1 (en) * 2019-05-23 2021-11-25 VelosBio Inc. Anti-ROR1/anti-CD3 bispecific binding molecules
JPWO2020250940A1 (es) * 2019-06-11 2020-12-17
CN110551222B (zh) * 2019-08-27 2023-06-06 重庆市畜牧科学院 一种新型双功能抗体及其用途
CN113015749B (zh) * 2019-09-30 2022-01-21 和铂医药(苏州)有限公司 靶向cd3的抗体、双特异性抗体及其用途
CN113493519B (zh) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2021254574A2 (en) * 2020-06-17 2021-12-23 Y-Mabs Therapeutics, Inc. Cd38 antibodies for the treatment of human diseases
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2541436T3 (es) * 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
SG10201912554TA (en) * 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
KR101472250B1 (ko) * 2005-10-12 2014-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2010265933B2 (en) * 2009-06-26 2015-05-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
RU2606264C2 (ru) * 2009-12-25 2017-01-10 Чугаи Сеияку Кабушики Каиша Способ полипептидной модификации для очистки полипептидных мультимеров
DK2580243T3 (da) * 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EA028804B1 (ru) * 2011-03-25 2018-01-31 Гленмарк Фармасьютикалс С.А. Гетеродимерные иммуноглобулины
AU2013322710A1 (en) * 2012-09-25 2015-04-16 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
ES2621377T3 (es) * 2012-11-05 2017-07-03 Morphosys Ag Anticuerpo marcado radiactivamente y usos del mismo
PE20160724A1 (es) * 2013-11-04 2016-08-04 Glenmark Pharmaceuticals Sa Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t

Also Published As

Publication number Publication date
PH12017500819A1 (en) 2017-10-02
CL2017001090A1 (es) 2018-01-05
EP3215541A1 (en) 2017-09-13
MX2017005814A (es) 2017-08-02
WO2016071355A1 (en) 2016-05-12
EA201790961A1 (ru) 2017-10-31
PE20171041A1 (es) 2017-07-19
AU2015341884B2 (en) 2020-09-17
JP7403505B2 (ja) 2023-12-22
MA40894A (fr) 2017-09-12
JP2018501297A (ja) 2018-01-18
KR20170078831A (ko) 2017-07-07
MY186929A (en) 2021-08-26
JP2019214582A (ja) 2019-12-19
BR112017009263A2 (pt) 2018-01-30
CA2965745A1 (en) 2016-05-12
NZ732019A (en) 2022-07-29
CN107207596A (zh) 2017-09-26
CA2965745C (en) 2023-12-05
AU2015341884A1 (en) 2017-06-08
EA039658B1 (ru) 2022-02-22
HK1244014A1 (zh) 2018-07-27
SG11201703313SA (en) 2017-05-30
JP2021184722A (ja) 2021-12-09
IL251848A0 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
CO2017005240A2 (es) Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción
ECSP17081420A (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
CO2018001485A2 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7 - h3 y cd3
CL2017001361A1 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
ECSP17040521A (es) Anticuerpos heterodiméricos que se unen a CD3 y a antígenos tumorales
CO2017006740A2 (es) Anticuerpos anti–cd79b
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
BR112016000903A2 (pt) anticorpos
CR20170059A (es) ANTICUERPOS Anti-LAG3 Y FRAGMENTOS DE UNIÓN A ANTÍGENO
UY35399A (es) Conjugados de fármacos con anticuerpos
CR20160506A (es) Anticuerpos biespecíficos que se unen a cd38 y cd3
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
CO2018013298A2 (es) Anticuerpos anti-gitr y sus usos.
CO2019011458A2 (es) Anticuerpo monoclonal para pd-l1
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
CL2019002735A1 (es) Anticuerpos que se unen a steap-1.
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
CL2020000920A1 (es) Anticuerpo monoclonal anti-il-5ra.
AR119964A2 (es) Anticuerpos anti-cd123 y conjugados y derivados de estos
CR20170222A (es) Anticuerpos heterodiméricos que se unen a cd3 y antígenos tumorales
CR20150083A (es) Proteinas de union a antigenos